Arcutis delivered a significant revenue beat driven by rapid ZORYVE adoption across atopic and seborrheic dermatitis markets. While EPS missed expectations due to elevated marketing and sales expansion costs, the company maintained positive operating cash flow and raised its full-year revenue outlook.
Key Highlights
- ZORYVE net product revenue reached $143.9 million, surging 45% year-over-year and exceeding the analyst estimate of $74.5 million.
- Management raised full-year 2026 net product sales guidance to a range of $535 million to $545 million, up from the previous $525 million to $540 million.
- The company generated $18.9 million in positive operating cash flow during the quarter, ending the period with $259.8 million in cash and marketable securities.